Nutropin Enhances Dental and Periodontal Health in U.S. Males with GHD
Reading Time: 3 minutesIntroduction Growth hormone deficiency (GHD) affects approximately 1 in 4,000 American males, manifesting as impaired somatic growth, reduced muscle mass, and craniofacial anomalies that extend to oral health. Nutropin (somatropin), a recombinant human growth hormone (rhGH), has emerged as a cornerstone therapy for GHD, approved by the U.S. Food and Drug Administration (FDA) since 1993. This article synthesizes recent evidence... Read more »
